Close Menu

NEW YORK (GenomeWeb News) – Metabolomics company Molecular Biometrics said yesterday that it has completed a $12.5 million Series B financing.

New investor Atlas Ventures led the financing round with participation from existing investors Safeguard Scientifics and Oxford Bioscience Partners.

Based in Norwood, Mass., Molecular Biometrics will use the cash to accelerate the global launch of its lead product, ViaMetrics-E, a rapid, non-invasive procedure designed to enhance in vitro fertilization outcomes by using cellular metabolomic signatures.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.

Michael Caputo, the top Department of Health and Human Service spokesperson, is taking a leave of absence, CNN says.

CNBC reports that the CDC Director says a SARS-CoV-2 vaccine isn't likely to be generally available until the third quarter of 2021, timing President Donald Trump disputes.

In Nature this week: MassIVE.quant resource houses mass spectrometry-based proteomic data, influence of Viking genetics on European populations, and more.

Oct
06
Sponsored by
10x Genomics

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disease characterized by irreversible scarring of the distal lung, leading to respiratory failure.